57 related articles for article (PubMed ID: 383292)
1. High-dose BCNU therapy with autologous bone marrow infusion: preliminary observations.
Spitzer G; Dicke KA; Verma DS; Zander A; McCredie KB
Cancer Treat Rep; 1979 Aug; 63(8):1257-64. PubMed ID: 383292
[TBL] [Abstract][Full Text] [Related]
2. Early pulmonary toxicity after administration of high-dose BCNU.
Litam JP; Dail DH; Spitzer G; Vellekoop L; Verma DS; Zander AR; Dicke KA
Cancer Treat Rep; 1981; 65(1-2):39-44. PubMed ID: 6261949
[TBL] [Abstract][Full Text] [Related]
3. Intravenous interleukin-2 just after high dose BCNU and autologous bone marrow transplantation. Report of a multicentric French pilot study.
Negrier S; Ranchere JY; Philip I; Merrouche Y; Biron P; Blaise D; Attal M; Rebattu P; Clavel M; Pourreau C
Bone Marrow Transplant; 1991 Oct; 8(4):259-64. PubMed ID: 1756323
[TBL] [Abstract][Full Text] [Related]
4. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
van Besien K; Tabocoff J; Rodriguez M; Andersson B; Mehra R; Przepiorka D; Dimopoulos M; Giralt S; Suki S; Khouri I
Bone Marrow Transplant; 1995 Apr; 15(4):549-55. PubMed ID: 7655380
[TBL] [Abstract][Full Text] [Related]
5. High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients.
Durando X; Lemaire JJ; Tortochaux J; Van-Praagh I; Kwiatkowski F; Vincent C; Bailly C; Verrelle P; Irthum B; Chazal J; Bay JO
Bone Marrow Transplant; 2003 Apr; 31(7):559-64. PubMed ID: 12692621
[TBL] [Abstract][Full Text] [Related]
6. High-dose cytoreductive therapy with autologous bone marrow transplantation in advanced malignancies.
Barbasch A; Higby DJ; Brass C; Bakri K; Karakousis C; Pontes JE; Wajsman LZ; Beckley S; Freeman A; Killion K; Burnett D
Cancer Treat Rep; 1983 Feb; 67(2):143-8. PubMed ID: 6337711
[TBL] [Abstract][Full Text] [Related]
7. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
Antman K; Eder JP; Elias A; Shea T; Peters WP; Andersen J; Schryber S; Henner WD; Finberg R; Wilmore D
Cancer Treat Rep; 1987 Feb; 71(2):119-25. PubMed ID: 3542208
[TBL] [Abstract][Full Text] [Related]
8. High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.
Ager S; Mahendra P; Richards EM; Bass G; Baglin TP; Marcus RE
Bone Marrow Transplant; 1996 Mar; 17(3):335-40. PubMed ID: 8704683
[TBL] [Abstract][Full Text] [Related]
9. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) autologous bone marrow transplantation therapy of refractory cancer: a preliminary report.
Phillips GL; Fay JW; Herzig GP; NaPombejara C; Wolff SN
Exp Hematol; 1979; 7 Suppl 5():372-83. PubMed ID: 400699
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.
Alessandrino EP; Bernasconi P; Colombo A; Caldera D; Martinelli G; Vitulo P; Malcovati L; Nascimbene C; Varettoni M; Volpini E; Klersy C; Bernasconi C
Bone Marrow Transplant; 2000 Feb; 25(3):309-13. PubMed ID: 10673703
[TBL] [Abstract][Full Text] [Related]
11. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
[TBL] [Abstract][Full Text] [Related]
13. Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation.
Johnson DB; Thompson JM; Corwin JA; Mosley KR; Smith MT; de los Reyes RA; Daly MB; Petty AM; Lamaster D; Pierson WP
J Clin Oncol; 1987 May; 5(5):783-9. PubMed ID: 3553437
[TBL] [Abstract][Full Text] [Related]
14. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.
Peppercorn J; Herndon J; Kornblith AB; Peters W; Ahles T; Vredenburgh J; Schwartz G; Shpall E; Hurd DD; Holland J; Winer E
Cancer; 2005 Oct; 104(8):1580-9. PubMed ID: 16118805
[TBL] [Abstract][Full Text] [Related]
15. Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia.
Zander AR; Vellekoop L; Spitzer G; Verma DS; Litam J; McCredie KB; Keating M; Hester JP; Dicke KA
Cancer Treat Rep; 1981; 65(5-6):377-81. PubMed ID: 7016323
[TBL] [Abstract][Full Text] [Related]
16. Long-term engraftment failure after marrow ablation and autologous hematopoietic reconstitution: differences between peripheral blood stem cell and bone marrow recipients.
Bentley SA; Brecher ME; Powell E; Serody JS; Wiley JM; Shea TC
Bone Marrow Transplant; 1997 Mar; 19(6):557-63. PubMed ID: 9085735
[TBL] [Abstract][Full Text] [Related]
17. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
van Besien K; Margolin K; Champlin R; Forman S
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
[TBL] [Abstract][Full Text] [Related]
18. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.
Phillips GL; Fay JW; Herzig GP; Herzig RH; Weiner RS; Wolff SN; Lazarus HM; Karanes C; Ross WE; Kramer BS
Cancer; 1983 Nov; 52(10):1792-802. PubMed ID: 6354414
[TBL] [Abstract][Full Text] [Related]
19. Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study.
Snyder MJ; Johnson DB; Daly MB; Giguere JK; Harman GH; Harden EA; Johnson RA; Leff RS; Mercier RJ; Messerschmidt GL
Bone Marrow Transplant; 1994 Oct; 14(4):595-600. PubMed ID: 7858534
[TBL] [Abstract][Full Text] [Related]
20. Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial.
Panella TJ; Smith DC; Schold SC; Rogers MP; Winer EP; Fine RL; Crawford J; Herndon JE; Trump DL
Cancer Res; 1992 May; 52(9):2456-9. PubMed ID: 1533174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
